Biosimilar Payments Under Medicare: On Closer Look, Is It Worth It?
This article was originally published in The Pink Sheet Daily
The Medicare Part B reimbursement scenario for biosimilars may offer limited incentives to marketers considering investing in follow-on products, according to Foley Hoag attorney Jayson Slotnik.
You may also be interested in...
Faced with a CBO estimate that H.R. 5651 will increase federal spending in fiscal years 2013 through 2022, the House Energy and Commerce Committee applies a section that speeds FDA decisions on some petitions to biosimilars. This contrasts with the Senate bill, which allows FDA to require brand companies to sell products covered by limited distribution systems to generic firms.
The promise of health care savings from an abundance of biosimilar drugs brought to market under recently passed reforms may go unfulfilled if intellectual property provisions of the law aren't addressed, members of a panel at the BIO annual meeting in Chicago said May 5
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.